Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Effector combining EFT508 and Bavencio

Julian Zhu
July 7, 2017 8:16 PM UTC

Effector Therapeutics Inc. (San Diego, Calif.) will conduct an open-label, Phase II trial evaluating EFT508 with or without PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) in patients with microsatellite stable relapsed or refractory colorectal cancer (CRC). The companies plan to start the trial in 3Q17 and share clinical costs.

EFT508 is a small molecule inhibitor of MAP kinase interacting serine-threonine kinase 1 (MKNK1; MNK1) and MKNK2 (MNK2). It is in Phase I/II testing to treat advanced solid tumors and lymphoma...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Effector Therapeutics Inc.

Merck KGaA

Pfizer Inc.